Star Equity (STRR) 10-K 20 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 13, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Entity Registrant Name	'DIGIRAD CORP	'	'
Entity Central Index Key	'0000707388	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Non-accelerated Filer	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	18,504,279	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$40,509,124

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
DIS	$37,171	$36,064	$37,794
Diagnostic Imaging	12,205	14,449	15,951
Total revenues	49,376	50,513	53,745
Cost of revenues:	'	'	'
DIS	27,828	27,293	29,672
Diagnostic Imaging	7,432	10,128	9,315
Total cost of revenues	35,260	37,421	38,987
Gross profit	14,116	13,092	14,758
Operating expenses:	'	'	'
Research and development	1,025	3,716	2,738
Marketing and sales	4,411	6,402	7,622
General and administrative	8,118	7,839	7,741
Amortization of intangible assets	231	233	331
Restructuring charges	1,728	0	-164
Gain on sale of assets and license agreement	-1,568	0	0
Total operating expenses	13,945	18,190	18,268
Income (loss) from operations	171	-5,098	-3,510
Other income (expense):	'	'	'
Interest and other income, net	63	101	267
Interest expense	-15	-4	-17
Total other income	48	97	250
Income (loss) before income taxes	219	-5,001	-3,260
Income tax benefit (expense)	45	77	-82
Net income (loss)	264	-4,924	-3,342
Net income (loss) per share:	'	'	'
Earnings Per Share, Basic (in dollars per share)	$0.01	($0.26)	($0.18)
Earnings Per Share, Diluted (in dollars per share)	$0.01	($0.26)	($0.18)
Shares used in per share computations:	'	'	'
Weighted average shares outstanding - basic (in dollars per share)	18,789	19,274	19,052
Weighted average shares outstanding - diluted (in dollars per share)	19,159	19,274	19,052
Common Stock, Dividends, Per Share, Declared	$0.05	$0	$0
Other Comprehensive loss:	'	'	'
Unrealized loss on marketable securities	-19	-16	-30
Total other comprehensive loss	-19	-16	-30
Comprehensive loss	245	-4,940	-3,372
Accumulated Other Comprehensive Income (Loss) [Member]	'	'	'
Other Comprehensive loss:	'	'	'
Unrealized loss on marketable securities	($19)	($16)	($30)

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$18,744	$19,514
Securities available-for-sale	7,673	7,679
Accounts receivable, net	5,430	6,329
Inventories, net	3,881	4,979
Other current assets	697	642
Restricted cash	244	244
Total current assets	36,669	39,387
Property and equipment, net	4,153	4,693
Property and equipment, net	353	584
Goodwill	184	184
Other assets	92	61
Total assets	41,451	44,909
Liabilities and stockholders' equity	'	'
Accounts payable	611	1,546
Accrued compensation	3,472	2,364
Accrued warranty	137	326
Deferred revenue	1,631	1,849
Other current liabilities	1,774	2,199
Total current liabilities	7,625	8,284
Other liabilities	440	176
Total liabilities	8,065	8,460
Commitments and contingencies (Note 6)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 18,504,279 and 19,144,448 shares issued and outstanding (net of treasury shares) at December 31, 2013 and 2012, respectively	2	2
Treasury stock, at cost; 2,588,484 shares and 1,073,641 shares at December 31, 2013 and 2012, respectively	-5,728	-2,086
Additional paid-in capital	156,968	156,634
Accumulated other comprehensive income (loss)	-2	17
Accumulated deficit	-117,854	-118,118
Total stockholders’ equity	33,386	36,449
Total liabilities and stockholders’ equity	$41,451	$44,909

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet Parentheticals (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	18,504,279	19,144,448
Common Stock, shares outstanding	18,504,279	19,144,448
Treasury stock, shares	2,588,484	1,073,641

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities	'	'	'
Net income (loss)	$264	($4,924)	($3,342)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:	'	'	'
Depreciation	1,682	1,898	2,765
Amortization of intangible assets	231	233	331
Provision for bad debts	-150	-30	237
Stock-based compensation	340	630	800
Gain on sale of assets and license agreement	-1,621	-104	-103
Amortization of premium on investments	192	140	286
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	1,049	21	970
Inventories	1,136	1,057	-1,046
Other assets	-86	127	6
Accounts payable	-935	216	-364
Accrued compensation	1,108	73	691
Deferred revenue	-218	-250	-280
Other liabilities	-791	-119	208
Restricted cash	0	-50	-194
Net cash provided by (used in) operating activities	2,201	-1,082	965
Investing activities	'	'	'
Purchases of property and equipment	-726	-936	-709
Net proceeds from sale of assets and license agreement	1,697	118	165
Business acquisition	0	-475	0
Purchases of securities available-for-sale	-4,679	-4,887	-13,086
Sales and maturities of securities available-for-sale	4,474	3,465	16,145
Net cash provided by (used in) investing activities	766	-2,715	2,515
Financing activities	'	'	'
Issuances of common stock	919	300	119
Repurchases of common stock	-3,642	-1,028	-19
Dividend paid	-925	0	0
Repayment of obligations under capital leases	-89	0	0
Net cash provided by (used in) financing activities	-3,737	-728	100
Net increase in cash and cash equivalents	-770	-4,525	3,580
Cash and cash equivalents at beginning of year	19,514	24,039	20,459
Cash and cash equivalents at end of year	$18,744	$19,514	$24,039

Consolidated_Statements_Of_Sto

Consolidated Statements Of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2010	$43,959	$2	($1,039)	$154,785	$63	($109,852)
Balance (shares) at Dec. 31, 2010	'	18,598,000	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation	800	'	'	800	'	'
Shares issued under stock incentive plans (shares)	'	313,000	'	'	'	'
Shares issued under stock incentive plans	119	'	'	119	'	'
Repurchases of common stock (shares)	'	-10,000	'	'	'	'
Repurchases of common stock	-19	'	-19	'	'	'
Net income (loss)	-3,342	'	'	'	'	-3,342
Unrealized loss on securities available-for-sale	-30	'	'	'	-30	'
Balance at Dec. 31, 2011	41,487	2	-1,058	155,704	33	-113,194
Balance (shares) at Dec. 31, 2011	'	18,901,000	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation	630	'	'	630	'	'
Shares issued under stock incentive plans (shares)	'	734,000	'	'	'	'
Shares issued under stock incentive plans	300	'	'	300	'	'
Repurchases of common stock (shares)	'	-491,000	'	'	'	'
Repurchases of common stock	-1,028	'	-1,028	'	'	'
Net income (loss)	-4,924	'	'	'	'	-4,924
Unrealized loss on securities available-for-sale	-16	'	'	'	-16	'
Balance at Dec. 31, 2012	36,449	2	-2,086	156,634	17	-118,118
Balance (shares) at Dec. 31, 2012	19,144,448	19,144,000	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation	340	'	'	340	'	'
Shares issued under stock incentive plans (shares)	'	875,000	'	'	'	'
Shares issued under stock incentive plans	919	'	'	919	'	'
Repurchases of common stock (shares)	'	-1,515,000	'	'	'	'
Repurchases of common stock	-3,642	'	-3,642	'	'	'
Dividend paid	-925	'	'	-925	'	'
Net income (loss)	264	'	'	'	'	264
Unrealized loss on securities available-for-sale	-19	'	'	'	-19	'
Balance at Dec. 31, 2013	$33,386	$2	($5,728)	$156,968	($2)	($117,854)
Balance (shares) at Dec. 31, 2013	18,504,279	18,504,000	'	'	'	'

The_Company_Notes

The Company (Notes)	12 Months Ended
	Dec. 31, 2013
The Company [Abstract]	'
The Company	'
	The Company
	Digirad Corporation (“Digirad”), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through our Digirad Imaging Solutions (“DIS”) segment. Through DIS, we provide in-office imaging services to physicians, offering certified personnel, required licensure, an imaging system and other support and supplies for the performance of nuclear and ultrasound imaging procedures under the supervision of our physician customers. DIS' physician customers enter into service contracts for imaging services generally delivered on a per-day basis. We also sell medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provide service on the products we sell through our Diagnostic Imaging segment. These two reportable segments, DIS and Diagnostic Imaging, are collectively referred to herein as the “Company.”
	The accompanying consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.

Basis_Of_Presentation_And_Sign

Basis Of Presentation And Significant Accounting Policies (Notes)	12 Months Ended
	Dec. 31, 2013
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies	'
	Basis of Presentation and Significant Accounting Policies
	Basis of Presentation
	The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles ("GAAP") and include the financial statements of the Company and its wholly owned subsidiaries. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates. All significant intercompany accounts and transactions have been eliminated. In addition certain reclassifications have been made to the prior year financial statements to conform to the current period presentation.
	Revenue Recognition
	We derive revenue primarily from providing in-office services to support the performance of cardiac diagnostic imaging procedures and from selling and servicing solid-state digital gamma cameras. We recognize revenue in accordance with the authoritative guidance for revenue recognition, when all of the following four criteria are met: (i) a contract or sales arrangement exists; (ii) products have been shipped and title has transferred or services have been rendered; (iii) the price of the products or services is fixed or determinable; and (iv) collectability is reasonably assured. The timing of revenue recognition is based upon factors such as passage of title and risk of loss, the need for installation, and customer acceptance. These factors are based on the specific terms of each contract or sales arrangement.
	DIS revenue is derived from our ability to provide our physician customers with our services, which includes use of our imaging system, qualified personnel, and related items required to perform imaging in their own offices and bill Medicare, Medicaid and other payors for in-office nuclear and ultrasound diagnostic imaging procedures. Revenue related to diagnostic imaging services is recognized at the time services are performed and collection is reasonably assured. DIS diagnostic imaging services are generally billed on a per-day basis under annual contracts for nuclear diagnostic imaging, which specifies the number of days of service to be provided, or on a flat rate month-to-month basis for ultrasound imaging.
	Diagnostic Imaging segment revenue is generated from the sales of gamma cameras and follow-on maintenance service contracts. We generally recognize revenue upon delivery and acceptance by customers. We also provide installation and training for camera sales in the United States. Installation and initial training services are generally performed shortly after delivery and represent costs which are accrued at the time revenue is recognized. Neither service is essential to the functionality of the product. Maintenance services are sold beyond the term of the warranty, which is generally one year from the date of purchase. Revenue from these contracts is deferred and recognized ratably over the service period and is included in Diagnostic Imaging sales.
	Multiple Element Arrangements
	In fiscal year 2013, we sold all of our assets specifically related to an uncommercialized surgical imaging system previously in development, as well as licensed certain existing Company technology. The transaction was accounted for in accordance with the authoritative guidance for multiple element arrangements. We identified the deliverables at the inception of the agreement and determined which items had value to the customer on a standalone basis, and were therefore separate units of accounting. Non-contingent arrangement consideration was allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each unit of accounting was determined using best estimate of selling price, because neither vendor specific objective evidence, or VSOE, of selling price or third-party evidence of selling price existed for the units of accounting. The non-contingent amount of arrangement consideration allocated to each unit of account was recognized upon performance and delivery of the related unit of accounting.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Significant estimates and judgments include those related to revenue recognition, multiple element arrangements, reserves for doubtful accounts and inventory valuation. Actual results could differ from those estimates.
	Concentration of Credit Risk and Significant Customers
	Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents, short-term investments and accounts receivable. We limit our exposure to credit loss by placing our cash and investments in high credit quality financial institutions and investment grade corporate debt securities. Additionally, we have established guidelines regarding diversification of our investments and their maturities, which are designed to maintain principal and maximize liquidity. No single customer represented greater than ten percent of our sales for any of the years presented.
	Fair Value of Financial Instruments
	The authoritative guidance for fair value measurements defines fair value for accounting purposes, establishes a framework for measuring fair value and provides disclosure requirements regarding fair value measurements. The guidance defines fair value as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Our financial instruments primarily consist of cash equivalents, securities available-for-sale, accounts receivable, other current assets, restricted cash, accounts payable and other current liabilities. The carrying amount of these financial instruments generally approximate fair value due to their short term nature. Securities available-for-sale are recorded at fair value.
	Cash and Cash Equivalents
	We consider all investments with a maturity of three months or less when acquired to be cash equivalents.
	Securities Available-for-Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the years ended December 31, 2013 and 2012.
	The following table sets forth the composition of securities available-for-sale as of December 31, 2013 and 2012 (in thousands):
	As of December 31, 2013		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		3 or less		$	7,675			$	—			$	(2	)	$	7,673
	As of December 31, 2012		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		3 or less		$	7,662			$	17			$	—		$	7,679
	Allowance for Doubtful Accounts and Billing Adjustments
	Accounts receivable consist principally of trade receivables from customers and are generally unsecured and due within 30 days. Expected credit losses related to trade accounts receivable are recorded as an allowance for doubtful accounts within accounts receivable, net in the consolidated balance sheets.
	We review reserves on a quarterly basis and make adjustments based on historical experience and known collectability issues and disputes. A provision for billing adjustments is charged against DIS revenues and a provision for doubtful accounts is charged to general and administrative expenses. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts.
	The following table summarizes our allowance for doubtful accounts and billing adjustments as of and for the years ended December 31, 2013, 2012 and 2011 (in thousands):
			Allowance for Doubtful Accounts (1)				Reserve for Billing
							Adjustments (2)
	Balance at December 31, 2010		$	1,187			$	412
	Provision		237				868
	Write-offs and recoveries, net		(676		)		(924		)
	Balance at December 31, 2011		748				356
	Provision		224				232
	Write-offs and recoveries, net		(459		)		(507		)
	Balance at December 31, 2012		513				81
	Provision (release)		(150		)		29
	Write-offs and recoveries, net		(93		)		(102		)
	Balance at December 31, 2013		$	270			$	8
	-1	The provision was charged against general and administrative expenses.
	-2	The provision was charged against revenue.
	Inventory
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis. Costs include material, labor and manufacturing overhead costs. We rely on historical information to support our excess and obsolete reserves and utilize our business judgment with respect to estimated future demand. Per our policy, we generally reserve 100% of the cost of inventory quantities in excess of a defined period of demand. Once inventory is reserved, we do not adjust the reserve balance until the inventory is sold or disposed.
	As a result of the Diagnostic Imaging restructuring initiative announced in February 2013, we recorded approximately $1.2 million of reserve for excess and obsolete inventory for the year ended December 31, 2012.
	The following table summarizes our reserves for excess and obsolete inventory as of and for the years ended December 31, 2013, 2012 and 2011 (in thousands):
		Reserve for Excess and
		Obsolete Inventories (1)
	Balance at December 31, 2010	$	1,891
	Provision	82
	Write-offs and scrap	(380		)
	Balance at December 31, 2011	1,593
	Provision	1,164
	Write-offs and scrap	(192		)
	Balance at December 31, 2012	2,565
	Provision	210
	Write-offs and scrap	(232		)
	Balance at December 31, 2013	$	2,543
	-1	The provision was charged against Diagnostic Imaging cost of revenues.
Long-Lived Assets including Finite Lived Purchased Intangible Assets
Long-lived assets consist of property and equipment and finite lived intangible assets. We record property and equipment at cost, and record other intangible assets based on their fair values at the date of acquisition. We calculate depreciation on property and equipment using the straight-line method over the estimated useful life of the assets which average 6 years for machinery and equipment, 3 years for computer hardware and software and the lower of the lease term or an average of 5 years for leasehold improvements. Charges related to amortization of assets recorded under capital leases is included within depreciation expense. We calculate amortization on other intangible assets using either the accelerated or the straight-line method over the estimated useful life of the assets, based on when we expect to receive cash inflows generated by the intangible assets.
Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. No impairment losses were recorded on long-lived assets during the years ended December 31, 2013, 2012 and 2011.
Valuation of Goodwill
We review goodwill for impairment on an annual basis during the fourth quarter, as well as when events or changes in circumstances indicate that the carrying value may not be recoverable. We begin the process by assessing qualitative factors in determining whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount. After performing the aforementioned assessment and upon review of the results of such assessment, we may begin performing step one of the two-step impairment analysis by quantitatively comparing the fair value of the reporting unit with goodwill to the carrying value of its long-term assets. If the carrying value of the long-term assets exceeds the fair value of the reporting unit, then we must perform the second step of the impairment test, whereby the carrying value of the reporting unit’s goodwill is compared to its implied fair value. If the carrying value of the goodwill exceeds the implied fair value, an impairment loss equal to the difference would be recorded.
Restricted Cash
As of December 31, 2013, we hold $0.2 million of money market funds that are restricted from withdrawal as they are held as collateral for a letter of credit related to an annual workers' compensation policy.
Restructuring
Restructuring costs are included in income (loss) from operations within the consolidated statements of comprehensive income (loss). Losses on property and equipment are recorded consistent with our accounting policy related to long-lived assets. One-time termination benefits are recorded at the time they are communicated to the affected employees. Losses on property lease obligations are recorded when the lease is abandoned or when the contract is terminated.
In February 2013, we announced a plan to restructure our Diagnostic Imaging business. In addition, we announced a plan in January 2014 to exit our 47,000 square foot former headquarters facility in Poway, California. See Note 10 to the audited consolidated financial statements for further information.
Shipping and Handling Fees and Costs
We record all shipping and handling billings to customers as revenue earned for the goods provided. Shipping and handling costs are included in cost of revenues and totaled $0.2 million, $0.2 million and $0.1 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Share-Based Compensation
We account for share-based awards exchanged for services in accordance with the authoritative guidance for share-based compensation. Under this guidance, share-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense, net of estimated forfeitures, over the requisite service period.
Warranty
We generally provide a 12 month warranty on our gamma cameras. We accrue the estimated cost of this warranty at the time revenue is recorded and charge warranty expense to Diagnostic Imaging cost of revenues. Warranty reserves are established based on historical experience with failure rates and repair costs and the number of systems covered by warranty. Warranty reserves are depleted as gamma cameras are repaired. The costs consist principally of materials, personnel, overhead and transportation. We review warranty reserves quarterly and, if necessary, make adjustments.
The activities related to our warranty reserve for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands):
		Years Ended December 31,
		2013				2012				2011
Balance at beginning of year		$	326			$	297			$	378
Charges to Diagnostic Imaging cost of revenues		149				453				708
Applied to liability		(338		)		(424		)		(789		)
Balance at end of year		$	137			$	326			$	297
Research and Development
Research and development costs are expensed as incurred.
Advertising Costs
Advertising costs are expensed as incurred. Total advertising costs for each of the years ended December 31, 2013, 2012 and 2011 were $0.3 million, $0.5 million and $0.6 million, respectively.
Basic and Diluted Net Income (Loss) Per Share
Basic earnings per share (EPS) is calculated by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding. Diluted EPS is computed by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding and the weighted average number of dilutive common stock equivalents, including stock options and non-vested restricted stock units under the treasury stock method. Common stock equivalents are only included in the diluted earnings per share calculation when their effect is dilutive. Shares used to compute basic net income (loss) per share include 44,522, 221,335, and 289,394 vested restricted stock units for the years ended December 31, 2013, 2012 and 2011, respectively.
The following table sets forth the computation of basic and diluted net income (loss) per share for the periods indicated (in thousands, except per share amounts):
		Years Ended December 31,
		2013				2012				2011
Net income (loss)		$	264			$	(4,924	)		$	(3,342	)
Shares used to compute basic net loss per share		18,789				19,274				19,052
Dilutive potential common shares:
Stock options		359				—				—
Restricted stock units		11				—				—
Shares used to compute diluted net loss per share		19,159				19,274				19,052
Basic net income (loss) per share		$	0.01			$	(0.26	)		$	(0.18	)
Diluted net income (loss) per share		$	0.01			$	(0.26	)		$	(0.18	)
Antidilutive common stock equivalents are excluded from the computation of diluted earnings per share. Stock options are antidilutive when the exercise prices of the stock options are greater than the average market price of the common shares. In addition, in periods where net losses are incurred, stock options with exercise prices less than the average market price of the common shares as well as unvested restricted stock units become antidilutive as well.
The number of stock options that were antidilutive due to an exercise price being greater than the average market price were 177,891, 268,662, 207,600 for the years ended December 31, 2013, 2012 and 2011, respectively.
Since we incurred net losses for the years ended December 31, 2012 and 2011, an incremental 403,670 and 601,491 common share equivalents were excluded from the computation of diluted net loss per share for years ended December 31, 2012 and 2011, respectively, as their effect would be antidilutive due to the net loss positions.
Other Comprehensive Income (Loss)
Other comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes unrealized gains or losses on our marketable securities.
Income Taxes
We account for income taxes in accordance with the related authoritative guidance, which sets forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not expected to be realized. In making such a determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
The authoritative guidance for income taxes defines a recognition threshold and measurement attributes for financial statement recognition and measurement of a tax provision taken or expected to be taken in a tax return. The guidance also provides direction on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Under the guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. We recognize interest and penalties related to uncertain tax positions as a component of the income tax provision.
Acquisition
On December 31, 2012, we acquired the operating assets of a nuclear and ultrasound imaging business located in the Southeastern U.S. The total purchase price was $500,000, including forgiveness of a $25,000 note receivable. Of the net purchase price, $340,000 was allocated to intangible assets and $135,000 to property, plant and equipment. The acquisition was accounted for as a business combination.
Accounting Standards Updates
In February 2013, the Financial Accounting Standards Board (FASB) issued guidance on disclosure requirements for items reclassified out of accumulated other comprehensive income. This new guidance requires entities to present (either on the face of the statement of operations or in the notes to the financial statements) the effects on the line items in the statement of operations for amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning on January 1, 2013. The adoption did not have an effect on our financial condition or results of operations, and only resulted in a change to financial statement presentation and disclosure.

Supplementary_Balance_Sheet_In

Supplementary Balance Sheet Information (Notes)	12 Months Ended
	Dec. 31, 2013
Supplementary Balance Sheet Disclosures [Abstract]	'
Supplementary Balance Sheet Information	'
	Supplementary Balance Sheet Information (in thousands):
			December 31,				December 31,
			2013				2012
	Inventories, net:
	Raw materials		$	2,619			$	2,522
	Work-in-process		3,189				3,161
	Finished goods		616				1,861
			6,424				7,544
	Less reserve for excess and obsolete inventories		(2,543		)		(2,565		)
			$	3,881			$	4,979
			December 31,				December 31,
			2013				2012
	Property and equipment, net:
	Machinery and equipment		$	22,596			$	22,302
	Computer hardware and software		2,497				2,827
	Leasehold improvements		861				865
			25,954				25,994
	Accumulated depreciation		(21,801		)		(21,301		)
			$	4,153			$	4,693
			31-Dec-13
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		3.5		$	2,940			$	(2,622	)	$	318
	Patents		4.9		141				(106		)	35
	Total intangible assets, net				$	3,081			$	(2,728	)	$	353
			31-Dec-12
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		3.6		2,940				(2,402		)	538
	Covenants not to compete		5		300				(300		)	—
	Patents		5.5		141				(95		)	46
	Total intangible assets, net				$	3,381			$	(2,797	)	$	584
	-1	Amortization expense for intangible assets, net for the years ended December 31, 2013, 2012 and 2011 was $0.2 million, $0.2 million and $0.3 million, respectively. Estimated amortization expense for intangible assets for 2014 is $0.1 million, for 2015 is $0.1 million, for 2016 is $0.1 million, for 2017 and thereafter is less than $0.1 million.
			December 31,				December 31,
			2013				2012
	Other current liabilities:
	Professional fees		$	367			$	319
	Sales and property taxes payable		275				211
	Radiopharmaceuticals and consumable medical supplies		242				238
	Current portion of capital lease obligation		174				41
	Facilities and related costs		151				216
	Outside services and consulting		134				208
	Legal reserve		50				385
	Other accrued liabilities		381				581
			$	1,774			$	2,199

Fair_Value_Measurements_Notes

Fair Value Measurements (Notes)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	We categorize our assets and liabilities measured at fair value into a three-level hierarchy in accordance with the authoritative guidance for fair value measurements. Assets and liabilities presented at fair value in our consolidated balance sheets are generally categorized as follows:
	Level 1:	Quoted prices in active markets for identical assets or liabilities.
	Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such assets and liabilities may have values determined using pricing models, discounted cash flow methodologies, or similar techniques, and include instruments for which the determination of fair value requires significant management judgment or estimation.
	As required by the authoritative guidance for fair value measurements, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of assets and liabilities and their placement within the fair value hierarchy levels. The following table sets forth by level within the fair value hierarchy our assets that were recorded at fair value as of December 31, 2013 and 2012 (in thousands).
			At Fair Value as of December 31, 2013
			Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities		$	—	$	7,673	$	—	$	7,673
			At Fair Value as of December 31, 2012
			Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities		$	—	$	7,679	$	—	$	7,679
	Our investments in corporate debt securities are valued based on quoted market prices for identical securities. Some of the corporate debt securities we hold do not trade on a daily basis. For investments that do not trade on a daily basis, we utilize a variety of pricing sources to determine fair value and corroborate the fair value by observing market data prior and subsequent to the balance sheet date.

Goodwill_Notes

Goodwill (Notes)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	Goodwill
	Goodwill has been recorded within a reporting unit of our DIS segment since the acquisition of net assets from Ultrascan. As a result of our annual impairment test during the fourth quarter of 2008, we recorded a $2.5 million impairment loss due to a significant decline in our market capitalization, adjusting goodwill to its current carrying value of $0.2 million. We determined the implied fair value of our goodwill utilizing the discounted cash flow method under the income approach. Under the income approach, we derived the fair value based on the present value of estimated future cash flows, which were based on historical data and assumptions pertaining to the market. In performing the 2013 goodwill impairment test, we assessed the relevant qualitative factors and concluded that it is more likely than not that the fair value of our goodwill is greater than the carrying amount. After reaching this conclusion, no further testing was performed. The qualitative factors we considered included, but were not limited to, general economic conditions, the industry outlook, our recent and forecasted financial performance and the price of our common stock. No impairment loss was recorded in 2013, 2012 or 2011.

Commitments_And_Contingencies_

Commitments And Contingencies (Notes)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments And Contingencies	'
	Commitments and Contingencies
	Leases
	We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from January 1, 2014 through October 31, 2017. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities. Rent expense was approximately $1.3 million for the years ended December 31, 2013, 2012 and 2011.
	As of December 31, 2013, we financed certain information technology and medical equipment and vehicles under capital leases. These obligations are secured by the specific equipment financed under each lease and will be repaid monthly over the remaining lease terms through November 30, 2017.
	We are committed to making future cash payments on non-cancelable operating leases and capital leases (including interest). The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of December 31, 2013 are as follows (in thousands):
		Operating		Capital
		Leases (1)		Leases
	2014	$	1,137	$	199
	2015	985		199
	2016	301		124
	2017	38		9
	2018	—		—
	Thereafter	—		—
	Total minimum lease payments	$	2,461	$	531
	(1) Operating leases amounts do not reflect the impact of the termination of the former headquarters lease in Poway, California, and subsequent entry into a lease for a separate 21,300 square foot facility in Poway, California. Both of the aforementioned events occurred subsequent to December 31, 2013. Refer to Note 10 of the consolidated financial statements for further detail.
	Radiopharmaceutical litigation. In April 2013, we settled a contractual dispute with our former radiopharmaceutical supplier who alleged that we, along with another radiopharmaceutical supplier, collaborated and breached our supply commitment contract. In summary, the settlement releases all parties from all claims associated with the dispute and the Company paid $385,000 which was recorded in other accrued liabilities as of December 31, 2012. The associated expense was recognized in the consolidated statement of comprehensive income (loss) for the year ended December 31, 2012.
	Annual Meeting Litigation. In May 2013, we were served with a complaint in Delaware Chancery Court by one of our larger shareholders, the Red Oak Fund, L.P. ("Red Oak"). In summary, the complaint alleged that the Annual Meeting of Shareholders election process (the "Election") was improperly conducted. Red Oak sought to have the results of the Election voided and to compel Digirad to conduct a new Annual Meeting process. On October 23, 2013, the Delaware Chancery Court issued a memorandum opinion in favor of the Company which upheld the Election as valid.
	Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Share_Based_Compensation_Notes

Share Based Compensation (Notes)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share Based Compensation	'
	Share-Based Compensation
	At December 31, 2013, we have two active stock option plans, the 2004 Stock Incentive Plan (the “2004 Plan”) and the 2011 Inducement Stock Incentive Plan (the “2011 Plan”), (collectively the “Plans”), under which stock options and restricted stock units may be granted to employees and non-employees, including members of our Board of Directors. Terms of any equity instruments granted under the Plans are approved by the Board of Directors. Stock options typically vest over the requisite service period of one to four years and have a contractual term of seven to ten years. Restricted stock units generally vest over one to three years and must be settled at the earlier of the recipients' termination date or 36 months after grant. Under the Plans, we are authorized to issue an aggregate of 2,750,000 shares of common stock. As of December 31, 2013, the Plans had 420,714 shares available for future issuance. The number of shares reserved for issuance under the 2004 Plan is subject to increase by any shares under the 1998 Stock Option/Stock Issuance Plan (the “1998 Plan”) that are forfeited, expire or are canceled up to a maximum of 1,500,000 shares. As of December 31, 2013, the number of shares provided for issuance under the 2004 Plan due to forfeited, expired and canceled shares under the 1998 Plan was 442,670 shares.
	Stock Options
	The estimated fair value of our stock options is determined using the Black-Scholes model. All stock options were granted with an exercise price equal to the fair value of the common stock on the grant date. The weighted-average grant date fair value of employee stock options granted during the years ended December 31, 2013, 2012 and 2011 was $1.06, $1.05 and $1.86 per share, respectively, which was estimated using the following weighted-average assumptions:
		Years Ended December 31,
		2013		2012			2011
	Expected volatility	56	%	59	%		62	%
	Expected term (in years)	4.6		6			6.5
	Risk-free interest rate	0.9	%	1.2	%		1.9	%
	Expected dividend yield	—		—			—
	The determination of the fair value of stock options using an option valuation model is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on the historical volatility of our common stock over a period of time equal to the expected term of the stock options. The expected term of our stock options is based on historical experience. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield in effect at the time of grant. At the time of grant for the fiscal year 2013 option grants, we had no plans to pay a dividend and no history of paying a dividend previously and as such an expected dividend yield of zero was utilized for purposes of determining fair value of the associated stock options.
	A summary of our stock option award activity as of and for the year ended December 31, 2013 is as follows (in thousands, except per share data):
		Number of		Weighted-				Weighted-			Aggregate
		Shares		Average				Average			Intrinsic  Value
				Exercise				Remaining
				Price per				Contractual
				Share				Term (In Years)
	Options outstanding at December 31, 2012	1,785		$	2.22
	Options exercisable at December 31, 2012	1,256		$	2.35
	Options granted	260		$	2.27
	Options forfeited	(157	)	1.87
	Options expired	(308	)	5.48
	Options exercised	(724	)	1.27
	Options outstanding at December 31, 2013	856		$	1.93			4.7			$	1,519
	Options exercisable at December 31, 2013	501		$	1.75			3.6			$	996
	As share-based compensation expense under the authoritative guidance for share-based payments is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. The guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	At December 31, 2013, total unrecognized compensation cost related to unvested stock options was $0.3 million, which is expected to be recognized over a weighted-average period of 3.1 years.
	Upon exercise, we issue new shares of common stock. Cash received from stock option exercises was $0.9 million during the year ended December 31, 2013, $0.3 million during the year ended December 31, 2012 and $0.1 million for the year ended December 31, 2011. We did not recognize any income tax benefits from stock option exercises as we continue to record a valuation allowance on our deferred tax assets, as more fully described in Note 8. The total intrinsic value of stock options exercised was $0.9 million during the year ended December 31, 2013, and less than $0.1 million during the years ended December 31, 2012 and 2011.
	Restricted Stock Units
	Under guidance for share-based payments, the fair value of our restricted stock awards is based on the grant date fair value of our common stock. All restricted stock units were granted with no purchase price. The weighted-average grant date fair value of the restricted stock units was $1.82 and $2.15 per share during the years ended December 31, 2012 and 2011, respectively. There were no restricted stock units granted during the year ended December 31, 2013.
	A summary of our restricted stock unit activity as of and for the year ended December 31, 2013 is as follows (in thousands, except per share data):
		Number of		Weighted-
		Shares		Average
				Grant Date
				Fair Value
				Per Share
	Non-vested restricted stock units outstanding at December 31, 2012	115		$	1.94
	Granted	—		$	—
	Forfeited	(46	)	$	1.89
	Vested	(69	)	$	1.98
	Non-vested restricted stock units outstanding at December 31, 2013	—		$	—
	The following table summarizes information about restricted stock units that vested during the years ended December 31, 2013, 2012 and 2011 based on service conditions (in thousands):
		Years Ended December 31,
		2013			2012				2011
	Fair value on vesting date of vested restricted stock units	$	136		$	350			$	507
	At December 31, 2013, there were no non-vested restricted stock units and therefore no unrecognized compensation cost related to non-vested restricted stock units.
	Allocation of Share-Based Compensation Expense
	Total share-based compensation expense related to all of our share-based units for the years ended December 31, 2013, 2012 and 2011 was allocated as follows (in thousands):
		Years Ended December 31,
	Cost of revenues:	2013			2012				2011
	DIS	$	6		$	7			$	13
	Diagnostic Imaging	49			82				99
	Research and development	9			78				84
	Marketing and sales	52			127				110
	General and administrative	224			336				494
	Share-based compensation expense	$	340		$	630			$	800

Income_Taxes_Notes

Income Taxes (Notes)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Significant components of the provision (benefit) for income taxes are as follows (in thousands):
		Years Ended December 31,
		2013				2012				2011
	Current provision (benefit):
	Federal	$	(49	)		$	(128	)		$	10
	State	4				51				72
	Total current provision (benefit)	(45		)		(77		)		82
	Deferred provision:
	Federal	—				—				—
	State	—				—				—
	Total deferred provision	—				—				—
	Total income tax provision (benefit)	$	(45	)		$	(77	)		$	82
	Differences between the provision (benefit) for income taxes and income taxes at the statutory federal income tax rate are as follows:
		Years Ended December 31,
		2013			2012			2011
	Income tax expense (benefit) at statutory federal rate	35	%		(35.0	)%		(35.0	)%
	State income tax expense (benefit), net of federal benefit	7.2	%		(2.9	)%		(2.7	)%
	Permanent differences and other	14.8	%		1.4	%		0.7	%
	Research and development credits, current year	(58.1	)%		(2.6	)%		(2.7	)%
	Research and development credits, prior year	(39.1	)%		—	%		—	%
	Change in effective state tax rates	(25.6	)%		2.4	%		10.3	%
	Expiration of net operating loss carryovers	8.2	%		36.6	%		9.4	%
	Stock compensation expense	53.7	%		—	%		(0.9	)%
	Reserve for uncertain tax positions and other reserves	5.4	%		(2.4	)%		3.1	%
	Change in valuation allowance	(22.2	)%		1	%		20.3	%
	Provision (benefit) for income taxes	(20.7	)%		(1.5	)%		2.5	%
	On January 3, 2013, the American Taxpayer Relief Act of 2012 was signed into law reinstating the federal research and development credit for the 2012 and 2013 years. Accordingly, we recorded the benefit related to the 2012 federal research and development credit of approximately $0.1 million in 2013.
	As of December 31, 2013, we had federal and state income tax net operating loss carry forwards of $95.5 million and $30.8 million, respectively. No federal loss carry forwards expired in 2013. Federal loss carry forwards will begin to expire in 2018, unless utilized before then. State loss carry forwards of approximately $0.1 million expired in 2013, and approximately $0.1 million is set to expire in 2014 unless utilized before then. We also have federal and California research and other credit carry forwards of approximately $1.8 million and $2.1 million, as of December 31, 2013, respectively. No federal credits expired in 2013. The remaining federal credits will begin to expire in 2018. The California research credits have no expiration. Pursuant to Internal Revenue Code Sections 382 and 383, use of our net operating loss and credit carry forwards may be limited because of a cumulative change in ownership greater than 50% which may have occurred or which may occur in the future. A valuation allowance has been recognized to offset the deferred tax assets, as realization of such assets has not met the “more likely than not” threshold required under the authoritative guidance of accounting for income taxes.
	Our net deferred tax assets consisted of the following (in thousands):
		As of December 31,
		2013				2012
	Deferred tax assets:
	Net operating loss carry forwards	$	34,727			$	34,588
	Research and development and other credits	1,928				1,836
	Reserves	1,273				1,531
	Intangibles	2,425				1,908
	Other, net	830				1,509
	Total deferred tax assets	41,183				41,372
	Deferred tax liabilities—depreciation	(300		)		(441		)
	Valuation allowance for deferred tax assets	(40,883		)		(40,931		)
	Net deferred tax assets	$	—			$	—
	The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
		December 31,
		2013				2012				2011
	Balance at beginning of year	$	1,539			$	1,621			$	1,617
	Increases related to prior year tax positions	5				25				30
	Increases related to current year tax positions	64				81				42
	Expiration of the statute of limitations for the assessment of taxes	(55		)		(252		)		(48		)
	Change in valuation allowances	—				64				(20		)
	Balance at end of year	$	1,553			$	1,539			$	1,621
	Included in the unrecognized tax benefits of $1.6 million at December 31, 2013 was $1.3 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance. We do not expect our unrecognized tax benefits to change significantly over the next 12 months.
	We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2008; however, our net operating loss carryforward and research credit carryforwards arising prior to that year are subject to adjustment. Our policy is to recognize interest expense and penalties related to income tax matters as a component of income tax benefit (expense). There were no accrued interest and penalties as of December 31, 2013 and 2012 and no interest and penalties were recognized during the years ended December 31, 2013, 2012 and 2011.

Employee_Retirement_Plan_Notes

Employee Retirement Plan (Notes)	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Employee Retirement Plan	'
	Employee Retirement Plan
	We have a 401(k) retirement plan under which employees may contribute up to 100% of their annual salary, within IRS limits. The Company contributions to the retirement plan totaled $0.2 million for each of the years ended December 31, 2013, 2012 and 2011.

Restructuring_Charges_Notes

Restructuring Charges (Notes)	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring Charges	'
	NOTE 10.	Restructuring Charges
	Diagnostic Imaging restructuring initiative
	On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and focus on maximizing cash flow from our DIS services business (the "Diagnostic Imaging restructuring initiative"). The Diagnostic Imaging restructuring initiative includes a reduction in force. In addition, as part of the Diagnostic Imaging restructuring initiative, we entered into an agreement in September 2013 with a third party to outsource the majority of the manufacturing associated with our cameras. As a result of this Diagnostic Imaging restructuring initiative, we estimate that we will incur in total approximately $1.7 million to $1.8 million in restructuring charges, the vast majority of which were incurred during fiscal year 2013. Included in this estimated range is approximately $1.6 million of employee related costs, while the remaining costs include contract termination costs and other related costs. Substantially all of the restructuring efforts associated with this initiative have been completed as of December 31, 2013. Through December 31, 2013, we have expensed approximately $1.7 million of charges associated with the Diagnostic Imaging restructuring initiative, including approximately $1.5 million of employee related costs. Restructuring liabilities and associated charges are measured at fair value as incurred. Restructuring charges do not include charges associated with excess inventory, any excess capacity, or personnel wages and benefits before personnel leave the Company.
	The following table includes information regarding our current Diagnostic Imaging restructuring initiative:
	(in thousands)		Accrued at December 31, 2012		Accrued Costs		Cash Payments and Other Reductions		Accrued at December 31, 2013
	Total Diagnostic Imaging restructuring initiative		$	—	$	1,728	$	1,239	$	489
	All accrued Diagnostic Imaging restructuring charges at December 31, 2013 are included in the accrued compensation line item in the audited consolidated balance sheets. All the Diagnostic Imaging restructuring charges for the year ended December 31, 2013 are included in the Diagnostic Imaging segment.
	Facilities restructuring initiative
	On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the "Facilities restructuring initiative"). This action was undertaken as the facility has excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.
	As a result of the facilities restructuring initiative, we estimate that we will incur in total approximately $0.6 million to $0.8 million in restructuring charges, which we anticipate to be incurred in the first half of fiscal year 2014. The estimated charges are comprised of lease termination, moving and other related costs. No charges were incurred as of December 31, 2013 related to this initiative.

Surgical_Imaging_Asset_Sale_an

Surgical Imaging Asset Sale and License Agreement (Notes)	12 Months Ended
	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Surgical Imaging Asset Sale and License Agreement	'
	Surgical Imaging Asset Sale and License Agreement
	On July 31, 2013, we entered into an asset purchase agreement with Novadaq Technologies Inc. (“Novadaq”). Under the terms of the asset purchase agreement, we sold Novadaq all of our assets specifically related to an uncommercialized surgical imaging system previously in development. We also licensed certain existing Company technology to Novadaq for their use in the peri-operative field. In exchange, we received upfront consideration of $2.0 million, and could receive up to $1.0 million in deferred contingent payments based on the achievement of specific regulatory and commercial milestones. In addition a royalty on sales, if any, will be paid for a period of five years from the date of the first commercial sale of the related surgical imaging system.
	We identified the deliverables at the inception of the agreements and determined that the tangible assets, consisting of inventory parts, and intangible assets, consisting of the technology license and various patents and know-how, individually represent separate units of accounting because each deliverable has standalone value. The best estimated selling prices for these units of accounting were determined using the income method for the intangible assets, and a cost plus a reasonable margin basis for the tangible assets. The arrangement consideration was allocated to the deliverables based on the relative selling price method.
	The amount of allocable arrangement consideration is limited to the amount that is not contingent upon meeting other specified performance conditions (the non-contingent amount); therefore, the amount allocated to the deliverables was limited to the upfront cash received of $2.0 million. Since performance and delivery occurred on both deliverables during the year ended December 31, 2013, a gain of $1.6 million representing the $2.0 million of upfront consideration less legal, consulting and other transaction fees as well as the cost basis of the inventory was recorded during the year ended December 31, 2013.
	We expect to recognize the regulatory and commercial milestone payments as a gain if and when the milestones are achieved. We expect to recognize the sales royalty payments as a gain if and when the royalties are earned.

Stock_Repurchase_Program_Notes

Stock Repurchase Program (Notes)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stock Repurchase Program	'
	Stock Repurchase Program
	On February 27, 2013, our board of directors modified our stock buyback program originally adopted in February 2009 to increase repurchases to an aggregate of $7.0 million, and subsequently, on March 13, 2013, increased the stock buyback program again for repurchases of up to an aggregate of $12.0 million. During the years ended December 31, 2013, 2012 and 2011, we repurchased 1,514,843, 490,816 and 9,607 shares of our common stock, respectively, under the stock buyback program. As of December 31, 2013, an aggregate of $6.3 million remains authorized for stock buyback under the program.

Preferred_Stock_Rights_Notes

Preferred Stock Rights (Notes)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Preferred Stock Rights	'
	Preferred Stock Rights
	On May 23, 2013, the Company's Board of Directors adopted a tax benefit preservation plan in the form of a Section 382 Rights Agreement (the “382 Agreement”). The 382 Agreement is intended to diminish the risk that our ability to use our net operating loss carryforwards to reduce future federal income tax obligations may become substantially limited due to an “ownership change,” as defined in Section 382 of the Internal Revenue Code. The Board authorized and declared a dividend distribution of one right for each outstanding share of common stock, par value $0.0001 per share, of the Company to stockholders of record as of the close of business on June 4, 2013. Each right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series B Participating Preferred Stock, par value $0.0001 per share, of the Company at an exercise price of $20.00 per one one-thousandth of a Preferred Share, subject to adjustment.
	The rights will become exercisable following (i) the 10th business day (or such later date as may be determined by the Board of Directors) after the public announcement that an acquiring person has acquired beneficial ownership of 4.99% or more of the common shares of the Company or (ii) the 10th business day (or such later date as may be determined by the Board of Directors) after a person or group announces a tender or exchange offer that would result in ownership by a person or group of 4.99% or more of the common shares of the Company.
	In addition, upon the occurrence of certain events, the exercise price of the rights would be adjusted and holders of the rights (other than rights owned by an acquiring person or group) would be entitled to purchase common stock at approximately half of market value. Given the potential adjustment of the exercise price of the rights, the rights could cause substantial dilution to a person or group that acquires 4.99% or more of the Company's common stock on terms not approved by the Company's Board of Directors.
	No rights were exercisable at December 31, 2013. There is no impact to the Company's financial results as a result of the adoption of the rights plan for the year ended December 31, 2013.

Segments_Notes

Segments (Notes)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segments	'
	Segments
	Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment. Summarized annual data for segments are as follows (in thousands):
		Years ended December 31,
		2013		2012			2011
	Gross profit by segment:
	DIS	$	9,343	$	8,771		$	8,122
	Diagnostic Imaging	4,773		4,321			6,636
	Consolidated gross profit	$	14,116	$	13,092		$	14,758
	Income (loss) from operations by segment:
	DIS	$	30	$	(48	)	$	(535	)
	Diagnostic Imaging (1)	141		(5,050		)	(2,975		)
	Consolidated income (loss) from operations	$	171	$	(5,098	)	$	(3,510	)
	Depreciation and amortization of tangible and intangible assets by segment:
	DIS	$	1,436	$	1,814		$	2,765
	Diagnostic Imaging	477		317			331
	Consolidated depreciation and amortization	$	1,913	$	2,131		$	3,096
		As of December 31,
		2013		2012
	Identifiable assets by segment:
	DIS	$	11,874	$	9,105
	Diagnostic Imaging	29,577		35,804
	Consolidated assets	$	41,451	$	44,909
	(1) Included in the Diagnostic Imaging income (loss) from operations for the year ended December 31, 2013, are approximately $1.7 million of charges associated with our Diagnostic Imaging restructuring initiative (See Note 10), as well as a gain of approximately $1.6 million associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 11).

Quaterly_Financial_Information

Quaterly Financial Information (Unaudited) (Notes)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information	'
	Quarterly Financial Information (Unaudited)
	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for fiscal 2013 and 2012 are as follows (in thousands, except per share data):
			1st			2nd			3rd			4th
			Quarter			Quarter			Quarter			Quarter
	Fiscal 2013
	Revenues		$	11,546		$	12,890		$	12,413		$	12,527
	Gross profit		$	2,817		$	3,793		$	3,818		$	3,688
	Income (loss) from operations (1)		$	(2,409	)	$	(632	)	$	2,432		$	780
	Net income (loss)		$	(2,419	)	$	(616	)	$	2,512		$	787
	Net income (loss) per common share—basic (2)		$	(0.13	)	$	(0.03	)	$	0.14		$	0.04
	Net income (loss) per common share—diluted (2)		$	(0.13	)	$	(0.03	)	$	0.14		$	0.04
	Fiscal 2012
	Revenues		$	12,969		$	12,710		$	11,817		$	13,017
	Gross profit		$	3,672		$	3,681		$	3,129		$	2,610
	Loss from operations		$	(1,282	)	$	(906	)	$	(1,067	)	$	(1,843	)
	Net loss		$	(1,268	)	$	(891	)	$	(906	)	$	(1,859	)
	Net loss per common share—basic and diluted (2)		$	(0.07	)	$	(0.05	)	$	(0.05	)	$	(0.10	)
	(1)	Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2013, are approximately $1.0 million, $0.6 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 10), as well as a gain of approximately $1.6 million in the third quarter of 2013 associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 11).
	(2)	Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

Subsequent_Event_Notes

Subsequent Event (Notes)	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Subsequent Events
	Telerhythmics Acquisition
	On March 13, 2014, we entered into a membership interest purchase agreement (the “Purchase Agreement”) to acquire 100% of the membership interest of Telerhythmics, LLC ("Telerhythmics"), a provider of 24 hour cardiac monitoring services.
	Under the terms of the Purchase Agreement, we paid to the sellers of the membership interest (the "Sellers") an aggregate of approximately $3.47 million in cash up front and assumed approximately $131,000 in debt. In addition, there is an earn-out opportunity of up to $501,000 over approximately three years based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (“EBITDA”) milestones. The Sellers will receive fifty percent of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are $415,000 for the period from the closing date through December 31, 2014, $825,000 for the period from January 1, 2015 through December 31, 2015, and $825,000 for the period from January 1, 2016 through December 31, 2016. The Purchase Agreement is also subject to a post-closing purchase price adjustment based on the final working capital balance, as defined in the Purchase Agreement.
	We expect to account for the transaction as a business combination and are in the process of determining the allocation of the purchase price to acquired assets and assumed liabilities, as well as preparing pro forma financial information.
	Facilities Restructuring
	On January 22, 2014, we entered into a termination agreement to end the lease on the 47,000 square foot former headquarter facility in Poway, California as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Under the termination agreement, we will pay a termination fee of $473,050. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations. The new lease agreement is for the term from March 1, 2014 through February 28, 2021.
	Dividend
	On February 3, 2014, the Company announced a dividend of $0.05 payable to shareholders of record as of February 14, 2014. The dividend was paid on February 24, 2014.

Basis_Of_Presentation_And_Sign1

Basis Of Presentation And Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles ("GAAP") and include the financial statements of the Company and its wholly owned subsidiaries. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates. All significant intercompany accounts and transactions have been eliminated. In addition certain reclassifications have been made to the prior year financial statements to conform to the current period presentation.
Revenue Recognition	'
	Revenue Recognition
	We derive revenue primarily from providing in-office services to support the performance of cardiac diagnostic imaging procedures and from selling and servicing solid-state digital gamma cameras. We recognize revenue in accordance with the authoritative guidance for revenue recognition, when all of the following four criteria are met: (i) a contract or sales arrangement exists; (ii) products have been shipped and title has transferred or services have been rendered; (iii) the price of the products or services is fixed or determinable; and (iv) collectability is reasonably assured. The timing of revenue recognition is based upon factors such as passage of title and risk of loss, the need for installation, and customer acceptance. These factors are based on the specific terms of each contract or sales arrangement.
	DIS revenue is derived from our ability to provide our physician customers with our services, which includes use of our imaging system, qualified personnel, and related items required to perform imaging in their own offices and bill Medicare, Medicaid and other payors for in-office nuclear and ultrasound diagnostic imaging procedures. Revenue related to diagnostic imaging services is recognized at the time services are performed and collection is reasonably assured. DIS diagnostic imaging services are generally billed on a per-day basis under annual contracts for nuclear diagnostic imaging, which specifies the number of days of service to be provided, or on a flat rate month-to-month basis for ultrasound imaging.
	Diagnostic Imaging segment revenue is generated from the sales of gamma cameras and follow-on maintenance service contracts. We generally recognize revenue upon delivery and acceptance by customers. We also provide installation and training for camera sales in the United States. Installation and initial training services are generally performed shortly after delivery and represent costs which are accrued at the time revenue is recognized. Neither service is essential to the functionality of the product. Maintenance services are sold beyond the term of the warranty, which is generally one year from the date of purchase. Revenue from these contracts is deferred and recognized ratably over the service period and is included in Diagnostic Imaging sales.
Use of Estimates and Changes of Estimate	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Significant estimates and judgments include those related to revenue recognition, multiple element arrangements, reserves for doubtful accounts and inventory valuation. Actual results could differ from those estimates.
Concentration of Credit Risk and Significant Customers	'
	Concentration of Credit Risk and Significant Customers
	Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents, short-term investments and accounts receivable. We limit our exposure to credit loss by placing our cash and investments in high credit quality financial institutions and investment grade corporate debt securities. Additionally, we have established guidelines regarding diversification of our investments and their maturities, which are designed to maintain principal and maximize liquidity. No single customer represented greater than ten percent of our sales for any of the years presented.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The authoritative guidance for fair value measurements defines fair value for accounting purposes, establishes a framework for measuring fair value and provides disclosure requirements regarding fair value measurements. The guidance defines fair value as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Our financial instruments primarily consist of cash equivalents, securities available-for-sale, accounts receivable, other current assets, restricted cash, accounts payable and other current liabilities. The carrying amount of these financial instruments generally approximate fair value due to their short term nature. Securities available-for-sale are recorded at fair value.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider all investments with a maturity of three months or less when acquired to be cash equivalents.
Securities Available-for-sale	'
	Securities Available-for-Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the years ended December 31, 2013 and 2012.
	The following table sets forth the composition of securities available-for-sale as of December 31, 2013 and 2012 (in thousands):
	As of December 31, 2013	Maturity in	Amortized Cost		Unrealized					Fair Value
		Years
					Gains		Losses
	Corporate debt securities	3 or less	$	7,675	$	—	$	(2	)	$	7,673
	As of December 31, 2012	Maturity in	Amortized Cost		Unrealized					Fair Value
		Years
					Gains		Losses
	Corporate debt securities	3 or less	$	7,662	$	17	$	—		$	7,679
Allowance for Doubtful Accounts and Billing Adjustments	'
	Allowance for Doubtful Accounts and Billing Adjustments
	Accounts receivable consist principally of trade receivables from customers and are generally unsecured and due within 30 days. Expected credit losses related to trade accounts receivable are recorded as an allowance for doubtful accounts within accounts receivable, net in the consolidated balance sheets.
	We review reserves on a quarterly basis and make adjustments based on historical experience and known collectability issues and disputes. A provision for billing adjustments is charged against DIS revenues and a provision for doubtful accounts is charged to general and administrative expenses. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts.
Inventory	'
	Inventory
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis. Costs include material, labor and manufacturing overhead costs. We rely on historical information to support our excess and obsolete reserves and utilize our business judgment with respect to estimated future demand. Per our policy, we generally reserve 100% of the cost of inventory quantities in excess of a defined period of demand. Once inventory is reserved, we do not adjust the reserve balance until the inventory is sold or disposed.
Valuation of Long-Lived Assets including Finite Lived Purchased Intangible Assets	'
	Long-Lived Assets including Finite Lived Purchased Intangible Assets
	Long-lived assets consist of property and equipment and finite lived intangible assets. We record property and equipment at cost, and record other intangible assets based on their fair values at the date of acquisition. We calculate depreciation on property and equipment using the straight-line method over the estimated useful life of the assets which average 6 years for machinery and equipment, 3 years for computer hardware and software and the lower of the lease term or an average of 5 years for leasehold improvements. Charges related to amortization of assets recorded under capital leases is included within depreciation expense. We calculate amortization on other intangible assets using either the accelerated or the straight-line method over the estimated useful life of the assets, based on when we expect to receive cash inflows generated by the intangible assets.
Valuation of Long Lived Assets including Finite Lived Purchased Intangible Assets	'
	Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.
Valuation of Goodwill	'
	Valuation of Goodwill
	We review goodwill for impairment on an annual basis during the fourth quarter, as well as when events or changes in circumstances indicate that the carrying value may not be recoverable. We begin the process by assessing qualitative factors in determining whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount. After performing the aforementioned assessment and upon review of the results of such assessment, we may begin performing step one of the two-step impairment analysis by quantitatively comparing the fair value of the reporting unit with goodwill to the carrying value of its long-term assets. If the carrying value of the long-term assets exceeds the fair value of the reporting unit, then we must perform the second step of the impairment test, whereby the carrying value of the reporting unit’s goodwill is compared to its implied fair value. If the carrying value of the goodwill exceeds the implied fair value, an impairment loss equal to the difference would be recorded.
Restricted Cash	'
	Restricted Cash
	As of December 31, 2013, we hold $0.2 million of money market funds that are restricted from withdrawal as they are held as collateral for a letter of credit related to an annual workers' compensation policy.
Restructuring	'
	Restructuring
	Restructuring costs are included in income (loss) from operations within the consolidated statements of comprehensive income (loss). Losses on property and equipment are recorded consistent with our accounting policy related to long-lived assets. One-time termination benefits are recorded at the time they are communicated to the affected employees. Losses on property lease obligations are recorded when the lease is abandoned or when the contract is terminated.
Shipping and Handling Fees and Costs	'
	Shipping and Handling Fees and Costs
	We record all shipping and handling billings to customers as revenue earned for the goods provided.
Share-Based Compensation	'
	Share-Based Compensation
	We account for share-based awards exchanged for services in accordance with the authoritative guidance for share-based compensation. Under this guidance, share-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense, net of estimated forfeitures, over the requisite service period.
Warranty	'
	Warranty
	We generally provide a 12 month warranty on our gamma cameras. We accrue the estimated cost of this warranty at the time revenue is recorded and charge warranty expense to Diagnostic Imaging cost of revenues. Warranty reserves are established based on historical experience with failure rates and repair costs and the number of systems covered by warranty. Warranty reserves are depleted as gamma cameras are repaired. The costs consist principally of materials, personnel, overhead and transportation. We review warranty reserves quarterly and, if necessary, make adjustments.
Research and Development	'
	Research and Development
	Research and development costs are expensed as incurred.
Advertising Costs	'
	Advertising Costs
	Advertising costs are expensed as incurred.
Net Loss Per Share	'
	Net Income (Loss) Per Share
	Basic earnings per share (EPS) is calculated by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding. Diluted EPS is computed by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding and the weighted average number of dilutive common stock equivalents, including stock options and non-vested restricted stock units under the treasury stock method. Common stock equivalents are only included in the diluted earnings per share calculation when their effect is dilutive.
Other Comprehensive Income (Loss)	'
	Other Comprehensive Income (Loss)
	Other comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes unrealized gains or losses on our marketable securities.
Income Taxes	'
	Income Taxes
	We account for income taxes in accordance with the related authoritative guidance, which sets forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not expected to be realized. In making such a determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
	The authoritative guidance for income taxes defines a recognition threshold and measurement attributes for financial statement recognition and measurement of a tax provision taken or expected to be taken in a tax return. The guidance also provides direction on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Under the guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. We recognize interest and penalties related to uncertain tax positions as a component of the income tax provision.
Acquisition	'
	Acquisition
	On December 31, 2012, we acquired the operating assets of a nuclear and ultrasound imaging business located in the Southeastern U.S. The total purchase price was $500,000, including forgiveness of a $25,000 note receivable. Of the net purchase price, $340,000 was allocated to intangible assets and $135,000 to property, plant and equipment. The acquisition was accounted for as a business combination.
Accounting Standards Updates	'
	Accounting Standards Updates
	In February 2013, the Financial Accounting Standards Board (FASB) issued guidance on disclosure requirements for items reclassified out of accumulated other comprehensive income. This new guidance requires entities to present (either on the face of the statement of operations or in the notes to the financial statements) the effects on the line items in the statement of operations for amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning on January 1, 2013. The adoption did not have an effect on our financial condition or results of operations, and only resulted in a change to financial statement presentation and disclosure.
Leases	'
	currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from January 1, 2014 through October 31, 2017. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities.
Commitments and Contingencies	'
	Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Basis_Of_Presentation_And_Sign2

Basis Of Presentation And Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Schedule of available-for-sale securities	'
	The following table sets forth the composition of securities available-for-sale as of December 31, 2013 and 2012 (in thousands):
	As of December 31, 2013		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		3 or less		$	7,675			$	—			$	(2	)	$	7,673
	As of December 31, 2012		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		3 or less		$	7,662			$	17			$	—		$	7,679
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the years ended December 31, 2013 and 2012.
Schedule of Company's allowance for doubtful accounts and billing adjustments	'
	The following table summarizes our allowance for doubtful accounts and billing adjustments as of and for the years ended December 31, 2013, 2012 and 2011 (in thousands):
			Allowance for Doubtful Accounts (1)				Reserve for Billing
							Adjustments (2)
	Balance at December 31, 2010		$	1,187			$	412
	Provision		237				868
	Write-offs and recoveries, net		(676		)		(924		)
	Balance at December 31, 2011		748				356
	Provision		224				232
	Write-offs and recoveries, net		(459		)		(507		)
	Balance at December 31, 2012		513				81
	Provision (release)		(150		)		29
	Write-offs and recoveries, net		(93		)		(102		)
	Balance at December 31, 2013		$	270			$	8
	-1	The provision was charged against general and administrative expenses.
	-2	The provision was charged against revenue.
Schedule of excess and obsolete inventory	'
	The following table summarizes our reserves for excess and obsolete inventory as of and for the years ended December 31, 2013, 2012 and 2011 (in thousands):
		Reserve for Excess and
		Obsolete Inventories (1)
	Balance at December 31, 2010	$	1,891
	Provision	82
	Write-offs and scrap	(380		)
	Balance at December 31, 2011	1,593
	Provision	1,164
	Write-offs and scrap	(192		)
	Balance at December 31, 2012	2,565
	Provision	210
	Write-offs and scrap	(232		)
	Balance at December 31, 2013	$	2,543
	-1	The provision was charged against Diagnostic Imaging cost of revenues.
Schedule of Company's warranty reserve activity	'
	The activities related to our warranty reserve for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands):
			Years Ended December 31,
			2013				2012				2011
	Balance at beginning of year		$	326			$	297			$	378
	Charges to Diagnostic Imaging cost of revenues		149				453				708
	Applied to liability		(338		)		(424		)		(789		)
	Balance at end of year		$	137			$	326			$	297
Schedule of basic and diluted net loss per share computations	'
	The following table sets forth the computation of basic and diluted net income (loss) per share for the periods indicated (in thousands, except per share amounts):
			Years Ended December 31,
			2013				2012				2011
	Net income (loss)		$	264			$	(4,924	)		$	(3,342	)
	Shares used to compute basic net loss per share		18,789				19,274				19,052
	Dilutive potential common shares:
	Stock options		359				—				—
	Restricted stock units		11				—				—
	Shares used to compute diluted net loss per share		19,159				19,274				19,052
	Basic net income (loss) per share		$	0.01			$	(0.26	)		$	(0.18	)
	Diluted net income (loss) per share		$	0.01			$	(0.26	)		$	(0.18	)

Supplementary_Balance_Sheet_In1

Supplementary Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2013
Supplementary Balance Sheet Disclosures [Abstract]	'
Supplemental Balance Sheet Information	'
	Supplementary Balance Sheet Information (in thousands):
			December 31,				December 31,
			2013				2012
	Inventories, net:
	Raw materials		$	2,619			$	2,522
	Work-in-process		3,189				3,161
	Finished goods		616				1,861
			6,424				7,544
	Less reserve for excess and obsolete inventories		(2,543		)		(2,565		)
			$	3,881			$	4,979
			December 31,				December 31,
			2013				2012
	Property and equipment, net:
	Machinery and equipment		$	22,596			$	22,302
	Computer hardware and software		2,497				2,827
	Leasehold improvements		861				865
			25,954				25,994
	Accumulated depreciation		(21,801		)		(21,301		)
			$	4,153			$	4,693
			31-Dec-13
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		3.5		$	2,940			$	(2,622	)	$	318
	Patents		4.9		141				(106		)	35
	Total intangible assets, net				$	3,081			$	(2,728	)	$	353
			31-Dec-12
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		3.6		2,940				(2,402		)	538
	Covenants not to compete		5		300				(300		)	—
	Patents		5.5		141				(95		)	46
	Total intangible assets, net				$	3,381			$	(2,797	)	$	584
	-1	Amortization expense for intangible assets, net for the years ended December 31, 2013, 2012 and 2011 was $0.2 million, $0.2 million and $0.3 million, respectively. Estimated amortization expense for intangible assets for 2014 is $0.1 million, for 2015 is $0.1 million, for 2016 is $0.1 million, for 2017 and thereafter is less than $0.1 million.
			December 31,				December 31,
			2013				2012
	Other current liabilities:
	Professional fees		$	367			$	319
	Sales and property taxes payable		275				211
	Radiopharmaceuticals and consumable medical supplies		242				238
	Current portion of capital lease obligation		174				41
	Facilities and related costs		151				216
	Outside services and consulting		134				208
	Legal reserve		50				385
	Other accrued liabilities		381				581
			$	1,774			$	2,199

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule Of Fair Value Measurements	'
		At Fair Value as of December 31, 2013
		Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities	$	—	$	7,673	$	—	$	7,673
		At Fair Value as of December 31, 2012
		Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities	$	—	$	7,679	$	—	$	7,679
	Our investments in corporate debt securities are valued based on quoted market prices for identical securities. Some of the corporate debt securities we hold do not trade on a daily basis. For investments that do not trade on a daily basis, we utilize a variety of pricing sources to determine fair value and corroborate the fair value by observing market data prior and subsequent to the balance sheet date.

Commitments_And_Contingencies_1

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Property Subject to or Available for Operating Lease	'
		Operating		Capital
		Leases (1)		Leases
	2014	$	1,137	$	199
	2015	985		199
	2016	301		124
	2017	38		9
	2018	—		—
	Thereafter	—		—
	Total minimum lease payments	$	2,461	$	531

Share_Based_Compensation_Table

Share Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	'
	The weighted-average grant date fair value of employee stock options granted during the years ended December 31, 2013, 2012 and 2011 was $1.06, $1.05 and $1.86 per share, respectively, which was estimated using the following weighted-average assumptions:
		Years Ended December 31,
		2013		2012			2011
	Expected volatility	56	%	59	%		62	%
	Expected term (in years)	4.6		6			6.5
	Risk-free interest rate	0.9	%	1.2	%		1.9	%
	Expected dividend yield	—		—			—
Schedule of Share-based Compensation, Stock Options, Activity	'
	A summary of our stock option award activity as of and for the year ended December 31, 2013 is as follows (in thousands, except per share data):
		Number of		Weighted-				Weighted-			Aggregate
		Shares		Average				Average			Intrinsic  Value
				Exercise				Remaining
				Price per				Contractual
				Share				Term (In Years)
	Options outstanding at December 31, 2012	1,785		$	2.22
	Options exercisable at December 31, 2012	1,256		$	2.35
	Options granted	260		$	2.27
	Options forfeited	(157	)	1.87
	Options expired	(308	)	5.48
	Options exercised	(724	)	1.27
	Options outstanding at December 31, 2013	856		$	1.93			4.7			$	1,519
	Options exercisable at December 31, 2013	501		$	1.75			3.6			$	996
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	'
	A summary of our restricted stock unit activity as of and for the year ended December 31, 2013 is as follows (in thousands, except per share data):
		Number of		Weighted-
		Shares		Average
				Grant Date
				Fair Value
				Per Share
	Non-vested restricted stock units outstanding at December 31, 2012	115		$	1.94
	Granted	—		$	—
	Forfeited	(46	)	$	1.89
	Vested	(69	)	$	1.98
	Non-vested restricted stock units outstanding at December 31, 2013	—		$	—
	The following table summarizes information about restricted stock units that vested during the years ended December 31, 2013, 2012 and 2011 based on service conditions (in thousands):
		Years Ended December 31,
		2013			2012				2011
	Fair value on vesting date of vested restricted stock units	$	136		$	350			$	507
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	'
	Allocation of Share-Based Compensation Expense
	Total share-based compensation expense related to all of our share-based units for the years ended December 31, 2013, 2012 and 2011 was allocated as follows (in thousands):
		Years Ended December 31,
	Cost of revenues:	2013			2012				2011
	DIS	$	6		$	7			$	13
	Diagnostic Imaging	49			82				99
	Research and development	9			78				84
	Marketing and sales	52			127				110
	General and administrative	224			336				494
	Share-based compensation expense	$	340		$	630			$	800

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		Years Ended December 31,
		2013				2012				2011
	Current provision (benefit):
	Federal	$	(49	)		$	(128	)		$	10
	State	4				51				72
	Total current provision (benefit)	(45		)		(77		)		82
	Deferred provision:
	Federal	—				—				—
	State	—				—				—
	Total deferred provision	—				—				—
	Total income tax provision (benefit)	$	(45	)		$	(77	)		$	82
Schedule of Net Deferred Tax Assets	'
	net deferred tax assets consisted of the following (in thousands):
		As of December 31,
		2013				2012
	Deferred tax assets:
	Net operating loss carry forwards	$	34,727			$	34,588
	Research and development and other credits	1,928				1,836
	Reserves	1,273				1,531
	Intangibles	2,425				1,908
	Other, net	830				1,509
	Total deferred tax assets	41,183				41,372
	Deferred tax liabilities—depreciation	(300		)		(441		)
	Valuation allowance for deferred tax assets	(40,883		)		(40,931		)
	Net deferred tax assets	$	—			$	—
Schedule of Effective Income Tax Rate Reconciliation	'
		Years Ended December 31,
		2013			2012			2011
	Income tax expense (benefit) at statutory federal rate	35	%		(35.0	)%		(35.0	)%
	State income tax expense (benefit), net of federal benefit	7.2	%		(2.9	)%		(2.7	)%
	Permanent differences and other	14.8	%		1.4	%		0.7	%
	Research and development credits, current year	(58.1	)%		(2.6	)%		(2.7	)%
	Research and development credits, prior year	(39.1	)%		—	%		—	%
	Change in effective state tax rates	(25.6	)%		2.4	%		10.3	%
	Expiration of net operating loss carryovers	8.2	%		36.6	%		9.4	%
	Stock compensation expense	53.7	%		—	%		(0.9	)%
	Reserve for uncertain tax positions and other reserves	5.4	%		(2.4	)%		3.1	%
	Change in valuation allowance	(22.2	)%		1	%		20.3	%
	Provision (benefit) for income taxes	(20.7	)%		(1.5	)%		2.5	%
Schedule of Unrecognized Tax Benefits Roll Forward	'
	The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
		December 31,
		2013				2012				2011
	Balance at beginning of year	$	1,539			$	1,621			$	1,617
	Increases related to prior year tax positions	5				25				30
	Increases related to current year tax positions	64				81				42
	Expiration of the statute of limitations for the assessment of taxes	(55		)		(252		)		(48		)
	Change in valuation allowances	—				64				(20		)
	Balance at end of year	$	1,553			$	1,539			$	1,621

Restructuring_Charges_Tables

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Costs	'
	The following table includes information regarding our current Diagnostic Imaging restructuring initiative:
	(in thousands)	Accrued at December 31, 2012		Accrued Costs		Cash Payments and Other Reductions		Accrued at December 31, 2013
	Total Diagnostic Imaging restructuring initiative	$	—	$	1,728	$	1,239	$	489

Segments_Tables

Segments (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment	'
		Years ended December 31,
		2013		2012			2011
	Gross profit by segment:
	DIS	$	9,343	$	8,771		$	8,122
	Diagnostic Imaging	4,773		4,321			6,636
	Consolidated gross profit	$	14,116	$	13,092		$	14,758
	Income (loss) from operations by segment:
	DIS	$	30	$	(48	)	$	(535	)
	Diagnostic Imaging (1)	141		(5,050		)	(2,975		)
	Consolidated income (loss) from operations	$	171	$	(5,098	)	$	(3,510	)
	Depreciation and amortization of tangible and intangible assets by segment:
	DIS	$	1,436	$	1,814		$	2,765
	Diagnostic Imaging	477		317			331
	Consolidated depreciation and amortization	$	1,913	$	2,131		$	3,096
		As of December 31,
		2013		2012
	Identifiable assets by segment:
	DIS	$	11,874	$	9,105
	Diagnostic Imaging	29,577		35,804
	Consolidated assets	$	41,451	$	44,909

Quaterly_Financial_Information1

Quaterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information	'
	Summarized quarterly data for fiscal 2013 and 2012 are as follows (in thousands, except per share data):
			1st			2nd			3rd			4th
			Quarter			Quarter			Quarter			Quarter
	Fiscal 2013
	Revenues		$	11,546		$	12,890		$	12,413		$	12,527
	Gross profit		$	2,817		$	3,793		$	3,818		$	3,688
	Income (loss) from operations (1)		$	(2,409	)	$	(632	)	$	2,432		$	780
	Net income (loss)		$	(2,419	)	$	(616	)	$	2,512		$	787
	Net income (loss) per common share—basic (2)		$	(0.13	)	$	(0.03	)	$	0.14		$	0.04
	Net income (loss) per common share—diluted (2)		$	(0.13	)	$	(0.03	)	$	0.14		$	0.04
	Fiscal 2012
	Revenues		$	12,969		$	12,710		$	11,817		$	13,017
	Gross profit		$	3,672		$	3,681		$	3,129		$	2,610
	Loss from operations		$	(1,282	)	$	(906	)	$	(1,067	)	$	(1,843	)
	Net loss		$	(1,268	)	$	(891	)	$	(906	)	$	(1,859	)
	Net loss per common share—basic and diluted (2)		$	(0.07	)	$	(0.05	)	$	(0.05	)	$	(0.10	)
	(1)	Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2013, are approximately $1.0 million, $0.6 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 10), as well as a gain of approximately $1.6 million in the third quarter of 2013 associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 11).
	(2)	Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

The_Company_Details

The Company (Details)	12 Months Ended
	Dec. 31, 2013
	segment
The Company [Abstract]	'
Number of reportable segments	2

Basis_Of_Presentation_And_Sign3

Basis Of Presentation And Significant Accounting Policies - Securities Available for Sale (Details) (Corporate Debt Securities, USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
two years or less [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale Securities, Amortized Cost	$7,675	$7,662
Available-for-sale Securities, Unrealized Gains	0	17
Available-for-sale Securities, Unrealized Losses	-2	0
Level 2	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale Securities, Fair Value	'	7,679
Level 2 | two years or less [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale Securities, Fair Value	$7,673	'

Basis_Of_Presentation_And_Sign4

Basis Of Presentation And Significant Accounting Policies - Allowance For Doubtful Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Allowance for doubtful accounts and billing adjustments [Roll Forward]	'		'		'
Provision	$1,200		'		'
Allowance for Doubtful Accounts	'		'		'
Allowance for doubtful accounts and billing adjustments [Roll Forward]	'		'		'
Balance	513	[1]	748	[1]	1,187	[1]
Provision	-150	[1]	224	[1]	237	[1]
Write-offs and recoveries, net	-93	[1]	-459	[1]	-676	[1]
Balance	270	[1]	513	[1]	748	[1]
Reserves for Billing Adjustments and Contractual Allowances	'		'		'
Allowance for doubtful accounts and billing adjustments [Roll Forward]	'		'		'
Balance	81	[2]	356	[2]	412	[2]
Provision	29	[2]	232	[2]	868	[2]
Write-offs and recoveries, net	-102	[2]	-507	[2]	-924	[2]
Balance	$8	[2]	$81	[2]	$356	[2]
[1]	The provision was charged against general and administrative expenses.
[2]	The provision was charged against revenue.

Basis_Of_Presentation_And_Sign5

Basis Of Presentation And Significant Accounting Policies - Reserves For Excess And Obsolete Inventories (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Provision	$1,200	'	'
Reserve For Excess and Obsolete Inventories	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Balance	2,565	1,593	1,891
Provision	210	1,164	82
Write-offs and srap	-232	-192	-380
Balance	$2,543	$2,565	$1,593

Basis_Of_Presentation_And_Sign6

Basis Of Presentation And Significant Accounting Policies - Warranty (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basis of Presentation and Significant Accounting Policies [Abstract]	'	'	'
Standard product warranty period	'P12M	'	'
Movement in Standard Product Warranty Accrual [Roll Forward]	'	'	'
Balance	$326	$297	$378
Charges to Diagnostic Imaging cost of revenues	149	453	708
Applied to liability	-338	-424	-789
Balance	$137	$326	$297

Basis_Of_Presentation_And_Sign7

Basis Of Presentation And Significant Accounting Policies - Net Income (Loss) Per Share (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Net Loss Per Share [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Vested restricted stock units used to compute basic net loss per share

'

'

'

'

221,335

'

'

'

44,522

'

289,394

Earnings Per Share, Basic and Diluted [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Net loss

$787

$2,512

($616)

($2,419)

($1,859)

($906)

($891)

($1,268)

$264

($4,924)

($3,342)

Shares used to compute basic net loss per share (in dollars per share)

'

'

'

'

'

'

'

'

18,789,000

19,274,000

19,052,000

Shares used to compute diluted net loss per share (in dollars per share)

'

'

'

'

'

'

'

'

19,159,000

19,274,000

19,052,000

Earnings Per Share, Basic (in dollars per share)

$0.04

[1]

$0.14

[1]

($0.03)

[1]

($0.13)

[1]

'

'

'

'

$0.01

($0.26)

($0.18)

Earnings Per Share, Diluted (in dollars per share)

$0.04

[1]

$0.14

[1]

($0.03)

[1]

($0.13)

[1]

'

'

'

'

$0.01

($0.26)

($0.18)

Stock Options

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic and Diluted [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Stock options

'

'

'

'

'

'

'

'

359,000

0

0

Restricted Stock Units (RSUs)

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic and Diluted [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Stock options

'

'

'

'

'

'

'

'

11,000

0

0

Stock Options

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic and Diluted [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Antidilutive common shares excluded from computation of diluted net loss

'

'

'

'

'

'

'

'

177,891

268,662

207,600

Common Stock [Member]

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic and Diluted [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Antidilutive common shares excluded from computation of diluted net loss

'

'

'

'

'

'

'

'

'

403,670

601,491

[1]

(2) Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

Basis_Of_Presentation_And_Sign8

Basis Of Presentation And Significant Accounting Policies - Acquisition (Details) (USD $)	Dec. 31, 2013
Business Acquisition [Line Items]	'
Total purchase price	$500,000
Note receivable forgiven	25,000
Net purchase price allocated to intangible assets	340,000
Net purchase price allocated to property, plant and equipment	$135,000

Basis_Of_Presentation_And_Sign9

Basis Of Presentation And Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Reserve for excess and obsolete inventory recorded	$1,200,000	'	'
Restricted cash	244,000	244,000	'
Shipping and handling costs	200,000	200,000	100,000
Advertising costs	$300,000	$500,000	$600,000
Machinery and Equipment	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful lives of the long-lived assets	'6 years	'	'
Computer hardware and software	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful lives of the long-lived assets	'3 years	'	'
Leasehold Improvements	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful lives of the long-lived assets	'5 years	'	'

Supplementary_Balance_Sheet_In2

Supplementary Balance Sheet Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Inventory, Net [Abstract]	'	'	'
Inventory, Raw Materials, Gross	$2,619,000	$2,522,000	'
Inventory, Work in Process, Gross	3,189,000	3,161,000	'
Inventory, Finished Goods, Gross	616,000	1,861,000	'
Inventory, Gross	6,424,000	7,544,000	'
Inventory, LIFO Reserve	-2,543,000	-2,565,000	'
Inventories, net	3,881,000	4,979,000	'
Property, Plant and Equipment, Net [Abstract]	'	'	'
Property and equipment, gross	25,954,000	25,994,000	'
Accumulated depreciation	-21,801,000	-21,301,000	'
Property and equipment, net	4,153,000	4,693,000	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangible assets, gross	3,081,000	3,381,000	'
Accumulated amortization	-2,728,000	-2,797,000	'
Finite-Lived Intangible Assets, Net	353,000	584,000	'
Property and equipment, net	353,000	584,000	'
Amortization of intangible assets	231,000	233,000	331,000
2013	100,000	'	'
2015	100,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	100,000	'	'
2016 and thereafter	100,000	'	'
Accrued Liabilities, Current [Abstract]	'	'	'
Outside services and consulting	367,000	319,000	'
Sales and property taxes payable	275,000	211,000	'
Professional fees	242,000	238,000	'
Radiopharmaceuticals and consumable medical supplies	174,000	41,000	'
Facilities and related costs	151,000	216,000	'
Travel expenses	134,000	208,000	'
Legal reserve	50,000	385,000	'
Otheraccrued liabilities	381,000	581,000	'
Other accrued liabilities	1,774,000	2,199,000	'
Leasehold Improvements	'	'	'
Property, Plant and Equipment, Net [Abstract]	'	'	'
Property and equipment, gross	861,000	865,000	'
Computer hardware and software	'	'	'
Property, Plant and Equipment, Net [Abstract]	'	'	'
Property and equipment, gross	2,497,000	2,827,000	'
Machinery and Equipment	'	'	'
Property, Plant and Equipment, Net [Abstract]	'	'	'
Property and equipment, gross	22,596,000	22,302,000	'
Customer Relationships	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Weighted average useful life	'3 years 6 months	'3 years 7 months 6 days	'
Intangible assets, gross	2,940,000	2,940,000	'
Accumulated amortization	-2,622,000	-2,402,000	'
Finite-Lived Intangible Assets, Net	318,000	538,000	'
Noncompete Agreements	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Weighted average useful life	'	'5 years	'
Intangible assets, gross	'	300,000	'
Accumulated amortization	'	-300,000	'
Finite-Lived Intangible Assets, Net	'	0	'
Patents	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Weighted average useful life	'4 years 10 months 24 days	'5 years 6 months	'
Intangible assets, gross	141,000	141,000	'
Accumulated amortization	-106,000	-95,000	'
Finite-Lived Intangible Assets, Net	$35,000	$46,000	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Corporate Debt Securities, USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Company's assets recorded at fair value	$0	$0
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Company's assets recorded at fair value	'	7,679
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Company's assets recorded at fair value	0	0
Total	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Company's assets recorded at fair value	7,673	7,679
two years or less [Member] | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Company's assets recorded at fair value	$7,673	'

Goodwill_Details

Goodwill (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2008	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Goodwill impairment loss	$2,500	$0	$0	$0
Goodwill	'	$184	$184	'

Commitments_And_Contingencies_2

Commitments And Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Operating lease rent expense	$1,300,000	$1,300,000	$1,300,000
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'
2013	1,137,000	'	'
Capital Leases, Future Minimum Payments Due, Next Twelve Months	199,000	'	'
2014	985,000	'	'
Capital Leases, Future Minimum Payments Due in Two Years	199,000	'	'
2015	301,000	'	'
Capital Leases, Future Minimum Payments Due in Three Years	124,000	'	'
2016	38,000	'	'
Capital Leases, Future Minimum Payments Due in Four Years	9,000	'	'
2017	0	'	'
Capital Leases, Future Minimum Payments Due in Five Years	0	'	'
Thereafter	0	'	'
Capital Leases, Future Minimum Payments Due Thereafter	0	'	'
Total minimum lease payments	2,461,000	'	'
Capital Leases, Future Minimum Payments Due	$531,000	'	'

Commitments_And_Contingencies_3

Commitments And Contingencies Loss Contingency, Settlement Agreement, Consideration (Details) (USD $)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Loss Contingency, Settlement Agreement, Consideration	$385,000

Share_Based_Compensation_Narra

Share Based Compensation - Narrative (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Aggregate number of shares of common stock authorized to issue under the Plans (shares)	2,750,000	'	'
Shares available for future issuance under the Plans (shares)	420,714	'	'
Cash received from the exercise of stock options during the period	$0.90	$0.30	$0.10
Stock Options	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock options contractual term under the Plans	'4 years 8 months 12 days	'	'
Weighted average grabnt-date fair value of options granted	$1.06	$1.05	$1.86
Unrecognized compensation cost	0.3	'	'
Expected recognition period for non-vested awards	'3 years 1 month 20 days	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	$0.90	$0.10	$0.10
Stock Options | Minimum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock options requisite service period under the Plans	'2 years	'	'
Stock options contractual term under the Plans	'7 years	'	'
Stock Options | Maximum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock options requisite service period under the Plans	'4 years	'	'
Stock options contractual term under the Plans	'10 years	'	'
Restricted Stock	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Restricted stock settlement period under the Plans	'36 months	'	'
Weighted average grant-date fair value of the restricted stock units	$0	$1.82	$2.15
Restricted Stock | Minimum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
restricted stock vesting period under the Plans	'1 year	'	'
Restricted Stock | Maximum [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
restricted stock vesting period under the Plans	'3 years	'	'
1998 Stock Option/Stock Issuance Plan	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Shares available for future issuance under the Plans (shares)	1,500,000	'	'
Number of shares reserved for issuance under the Plans	442,670	'	'

Share_Based_Compensation_Stock

Share Based Compensation - Stock Options Fair Value Weighted Average Valuation Assumptions (Details) (Stock Options)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected volatility	56.00%	59.00%	62.00%
Expected term (in years)	'4.6	'6.0	'6.5
Risk-free interest rate	0.90%	1.20%	1.90%
Expected dividend yield	0.00%	0.00%	0.00%

Share_Based_Compensation_Stock1

Share Based Compensation - Stock Options Activity (Details) (Stock Options, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	$900,000	$100,000	$100,000
Number of Shares [Roll Forward]	'	'	'
Options outstanding at December 31, 2011 (shares)	1,785	'	'
Options exercisable at December 31, 2011 (shares)	1,256	'	'
Options granted (shares)	260	'	'
Options forfeited (shares)	-157	'	'
Options expired (shares)	-308	'	'
Options exercised (shares)	-724	'	'
Options outstanding at December 31, 2012 (shares)	856	1,785	'
Options exercisable at December 31, 2012 (shares)	501	1,256	'
Weighted Average Exercise Price per Share [Roll Forward]	'	'	'
Options outstanding at December 31, 2011 - Weighted Average Exercise Price per Share (US$ per share)	$2.22	'	'
Options exercisable at December 31, 2011 - Weighted Average Exercise Price per Share (US$ per share)	$2.35	'	'
Options granted - Weighted Average Exercise Price per Share (US$ pre share)	$2.27	'	'
Options forfeited - Weighted Average Exercise Price per Share (US$ per share)	$1.87	'	'
Options expired - Weighted Average Exercise Price per Share (US$ per share)	$5.48	'	'
Options exercised - Weighted Average Exercise Price per Share (US$ per share)	$1.27	'	'
Options outstanding at December 31, 2012 - Weighted Average Exercise Price per Share (US$ per share)	$1.93	$2.22	'
Options exercisable at December 31, 2012 - Weighted Average Exercise Price per Share (US$ per share)	$1.75	$2.35	'
Options outstanding - Weighted Average Remaining Contractual Term (in years)	'4 years 8 months 12 days	'	'
Options exercisable - Weighted Average Remaining Contractual Term (in years)	'3 years 7 months 6 days	'	'
Options outstanding at December 31, 2012 - Aggregate Intrinsic Value	1,519,000	'	'
Options exercisable at December 31, 2012 - Aggregate Intrinsic Value	$996,000	'	'

Share_Based_Compensation_Restr

Share Based Compensation - Restricted Stock Activity (Details) (Restricted Stock, USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restricted Stock	'	'	'
Nonvested Resticted Stock Units - Number of Shares [Roll Forward]	'	'	'
Non-vested restricted stock units outstanding at December 31, 2011 (shares)	0	115	'
Granted (shares)	0	'	'
Forfeited (shares)	-46	'	'
Vested (shares)	-69	'	'
Non-vested restricted stock units outstanding at December 31, 2011 (shares)	0	115	'
Nonvested Restricted Stock Units - Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'
Non-vested restricted stock units outstanding at December 31, 2011 - Weighted Average Grant Date Fair Value	$1.94	'	'
Granted (US$ per share)	$0	$1.82	$2.15
Forfeited (US$ per share)	$1.89	'	'
Vested (US$ per share)	$1.98	'	'
Non-vested restricted stock units outstanding at December 31, 2011 - Weighted Average Grant Date Fair Value	$0	$1.94	'
Fair value on vesting date of vested restricted stock units	$136	$350	$507

Share_Based_Compensation_Alloc

Share Based Compensation - Allocation of Share-based Compensation Expense (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$340	$630	$800
DIS	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	6	7	13
Diagnostic Imaging	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	49	82	99
Research and development	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	9	78	84
Marketing and sales	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	52	127	110
General and administrative	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$224	$336	$494

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating Loss Carryforwards [Line Items]	'	'	'	'
Income Tax Reconciliation, Tax Credits, Research	$100,000	'	'	'
State income tax net operating loss carryforwards	30,800,000	'	'	'
Unrecognized Tax Benefits - Balance at end of year	1,553,000	1,539,000	1,621,000	1,617,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1,300,000	'	'	'
Internal Revenue Service (IRS) [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Federal income tax net operating loss carryforwards	95,500,000	'	'	'
Foreign Tax Authority [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Federal and California research and other credit carryforwards	1,800,000	'	'	'
Federal And California Tax Authority [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Federal and California research and other credit carryforwards	2,100,000	'	'	'
Expiring In Next Twelve Months [Member] | State and Local Jurisdiction [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	100,000	'	'	'
Expiring In Year Two [Member] | State and Local Jurisdiction [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
State loss carryforward subject to expiration	$100,000	'	'	'

Income_Taxes_Income_Tax_Provis

Income Taxes - Income Tax Provision (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Current Federal Tax Expense (Benefit)	($49)	($128)	$10
Current State and Local Tax Expense (Benefit)	4	51	72
Current Income Tax Expense (Benefit)	-45	-77	82
Deferred Federal Income Tax Expense (Benefit)	0	0	0
Deferred State and Local Income Tax Expense (Benefit)	0	0	0
Deferred Income Tax Expense (Benefit)	0	0	0
Income Tax Expense (Benefit)	($45)	($77)	$82

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Effective Income Tax Rate Reconciliation Line Items [Abstract]	'	'	'
Income tax expense (benefit) at statutory federal rate	35.00%	-35.00%	-35.00%
State income tax expense (benefit), net of federal benefit	7.20%	-2.90%	-2.70%
Permanent differences and other	14.80%	1.40%	0.70%
Research and development credits, current year	-58.10%	-2.60%	-2.70%
Research and development credits, prior year	-39.10%	0.00%	0.00%
Change in effective state tax rates	-25.60%	2.40%	10.30%
Expiration of net operating loss carryovers	8.20%	36.60%	9.40%
Stock compensation expense	53.70%	0.00%	-0.90%
Reserve for uncertain tax positions and other reserves	5.40%	-2.40%	3.10%
Change in valuation allowance	-22.20%	1.00%	20.30%
Provision (benefit) for income taxes	-20.70%	-1.50%	2.50%

Income_Taxes_Net_Deferred_Tax_

Income Taxes - Net Deferred Tax Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Net operating loss carry forwards	$34,727	$34,588
Research and development and other credits	1,928	1,836
Reserves	1,273	1,531
Intangibles	2,425	1,908
Other, net	830	1,509
Total deferred tax assets	41,183	41,372
Deferred tax liabilities—depreciation	-300	-441
Valuation allowance for deferred tax assets	-40,883	-40,931
Net deferred tax assets	$0	$0

Income_Taxes_Unrecognized_Tax_

Income Taxes - Unrecognized Tax Benefit Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$1,300,000	'	'
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Unrecognized Tax Benefits - Balance at beginning of year	1,539,000	1,621,000	1,617,000
Change in valuation amount	0	64,000	-20,000
Expiration of the statute of limitations for the assessment of taxes	-55,000	-252,000	-48,000
Increases related to current year tax positions	64,000	81,000	42,000
Increases related to prior year tax positions	5,000	25,000	30,000
Unrecognized Tax Benefits - Balance at end of year	$1,553,000	$1,539,000	$1,621,000

Employee_Retirement_Plan_Detai

Employee Retirement Plan (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]	'	'
Maximum annual contribution of annual salary per employee	100.00%	'
The Company's contributions to its retirement plans	$0.20	$0.20

Restructuring_Charges_Diagnost

Restructuring Charges - Diagnostic Imaging Restructuring Initiative (Details) (USD $)	3 Months Ended			12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Accrued Costs	$100,000	$600,000	$1,000,000	$1,728,000	$0	($164,000)
Diagnostic Imaging Initiative [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Accrued at December 31, 2012	'	'	0	0	'	'
Accrued Costs	'	'	'	1,728,000	'	'
Cash Payments and Other Reductions	'	'	'	1,239,000	'	'
Restructuring Reserve	'	'	'	489,000	'	'
Diagnostic Imaging Initiative [Member] | Employee Severance [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Accrued Costs	'	'	'	1,500,000	'	'
Restructuring and Related Cost, Expected Cost	'	'	'	1,600,000	'	'
Diagnostic Imaging Initiative [Member] | Minimum [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Restructuring and Related Cost, Expected Cost	'	'	'	1,700,000	'	'
Diagnostic Imaging Initiative [Member] | Maximum [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Restructuring and Related Cost, Expected Cost	'	'	'	$1,800,000	'	'

Restructuring_Charges_Faciliti

Restructuring Charges - Facilities Restructuring Initiative (Details) (Facilities Restructuring Initiative [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Jan. 24, 2014	Jan. 23, 2014
	Minimum [Member]	Maximum [Member]	Subsequent Event [Member]	Subsequent Event [Member]
			sqft	sqft
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Approximate square footage of manufacturing and office space	'	'	47,000	21,300
Restructuring and Related Cost, Expected Cost	$0.60	$0.80	'	'

Surgical_Imaging_Asset_Sale_an1

Surgical Imaging Asset Sale and License Agreement (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 31, 2013	Jul. 31, 2013
				Novadaq Technologies [Member]	Regulatory And Commercial Milestones [Member]
					Novadaq Technologies [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Proceeds from Sale of Machinery and Equipment	'	'	'	$2,000,000	'
Deferred Contingent Payments, Maximum Consideration That Can Be Received	'	'	'	'	1,000,000
Gain on disposition of assets	$1,568,000	$0	$0	'	'

Stock_Repurchase_Program_Detai

Stock Repurchase Program (Details) (2009 Stock Repurchase Program [Member], USD $)	0 Months Ended		12 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 13, 2013	Feb. 26, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
				Common Stock [Member]	Common Stock [Member]	Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]	'	'	'	'	'	'
Stock Repurchase Program, Authorized Amount	$12	$7	'	'	'	'
Stock Repurchased During Period, Shares	'	'	'	1,514,843	490,816	9,607
Stock Repurchase Program, Remaining Authorized Repurchase Amount	'	'	$6.30	'	'	'

Preferred_Stock_Rights_Narrati

Preferred Stock Rights (Narrative) (Details) (USD $)	Dec. 31, 2013	Jun. 04, 2013	Dec. 31, 2012	Jun. 04, 2013	Jun. 04, 2013
				Series B Preferred Stock [Member]	Common Stock [Member]
Class of Stock [Line Items]	'	'	'	'	'
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	$0.00	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	'	$0.00	$0.00	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	'	'	20	'
Class of Warrant, Covenant For Exercisibility, Common Stock Ownership Percentage	'	'	'	'	4.99%

Segments_Details

Segments (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Consolidated gross profit

$3,688

$3,818

$3,793

$2,817

$2,610

$3,129

$3,681

$3,672

$14,116

$13,092

$14,758

Consolidated loss from operations

780

[1]

2,432

[1]

-632

[1]

-2,409

[1]

-1,843

-1,067

-906

-1,282

171

-5,098

-3,510

Consolidated depreciation and amortization

'

'

'

'

'

'

'

'

1,913

2,131

3,096

Consolidated assets

41,451

'

'

'

44,909

'

'

'

41,451

44,909

'

Restructuring charges

'

100

600

1,000

'

'

'

'

1,728

0

-164

Gain on disposition of assets

'

'

'

'

'

'

'

'

1,568

0

0

DIS

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Consolidated gross profit

'

'

'

'

'

'

'

'

9,343

8,771

8,122

Consolidated loss from operations

'

'

'

'

'

'

'

'

30

-48

-535

Consolidated depreciation and amortization

'

'

'

'

'

'

'

'

1,436

1,814

2,765

Consolidated assets

11,874

'

'

'

9,105

'

'

'

11,874

9,105

'

Diagnostic Imaging

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Consolidated gross profit

'

'

'

'

'

'

'

'

4,773

4,321

6,636

Consolidated loss from operations

'

'

'

'

'

'

'

'

141

[2]

-5,050

[2]

-2,975

[2]

Consolidated depreciation and amortization

'

'

'

'

'

'

'

'

477

317

331

Consolidated assets

$29,577

'

'

'

$35,804

'

'

'

$29,577

$35,804

'

[1]

(1) Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2013, are approximately $1.0 million, $0.6 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 10), as well as a gain of approximately $1.6 million in the third quarter of 2013 associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 11).

[2]

Included in the Diagnostic Imaging income (loss) from operations for the year ended December 31, 2013, are approximately $1.7 million of charges associated with our Diagnostic Imaging restructuring initiative (See Note 10), as well as a gain of approximately $1.6 million associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 11).

Quaterly_Financial_Information2

Quaterly Financial Information (Unaudited) (Details) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'		'		'		'		'		'		'		'		'	'	'
Restructuring charges	'		$100		$600		$1,000		'		'		'		'		$1,728	$0	($164)
Revenue	12,527		12,413		12,890		11,546		13,017		11,817		12,710		12,969		37,171	36,064	37,794
Gross profit	3,688		3,818		3,793		2,817		2,610		3,129		3,681		3,672		14,116	13,092	14,758
Loss from operations	780	[1]	2,432	[1]	-632	[1]	-2,409	[1]	-1,843		-1,067		-906		-1,282		171	-5,098	-3,510
Net income (loss)	787		2,512		-616		-2,419		-1,859		-906		-891		-1,268		264	-4,924	-3,342
Earnings Per Share, Basic (in dollars per share)	$0.04	[2]	$0.14	[2]	($0.03)	[2]	($0.13)	[2]	'		'		'		'		$0.01	($0.26)	($0.18)
Earnings Per Share, Diluted (in dollars per share)	$0.04	[2]	$0.14	[2]	($0.03)	[2]	($0.13)	[2]	'		'		'		'		$0.01	($0.26)	($0.18)
Net income (loss) per common share - basic and diluted (US$ per share)	'		'		'		'		($0.10)	[2]	($0.05)	[2]	($0.05)	[2]	($0.07)	[2]	'	'	'
Gain on sale of assets and license agreement	'		'		'		'		'		'		'		'		($1,568)	$0	$0
[1]	(1) Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2013, are approximately $1.0 million, $0.6 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 10), as well as a gain of approximately $1.6 million in the third quarter of 2013 associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 11).
[2]	(2) Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

Subsequent_Event_Telerhythmics

Subsequent Event - Telerhythmics Acquisition (Details) (Subsequent Event [Member], USD $)	Mar. 13, 2014
Subsequent Event [Line Items]	'
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Business Acquisition, Cost of Acquired Entity, Cash Paid	$3,500,000
Business Acquisition, Purchase Price Allocation, Liabilities Assumed	131,000
Subsequent Event, Amount	501,000
Year one [Member]	'
Subsequent Event [Line Items]	'
Subsequent Event, Amount	415,000
Year two [Member]	'
Subsequent Event [Line Items]	'
Subsequent Event, Amount	825,000
Year three [Member]	'
Subsequent Event [Line Items]	'
Subsequent Event, Amount	$825,000

Subsequent_Event_Facilities_Re

Subsequent Event - Facilities Restructuring (Details) (Subsequent Event [Member], USD $)	Jan. 24, 2014	Jan. 23, 2014
	sqft	sqft
Subsequent Event [Line Items]	'	'
Restructuring Reserve	473,050	'
Facilities Restructuring Initiative [Member]	'	'
Subsequent Event [Line Items]	'	'
Area of Real Estate Property	47,000	21,300

Subsequent_Event_Dividend_Paya

Subsequent Event - Dividend Payable (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Feb. 03, 2014
				Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'
Common Stock, Dividends, Per Share, Declared	$0.05	$0	$0	$0.05